Table 1.
Summary of the characteristics of the cohorts included in the meta-analysis
| Characteristics | Number of cohorts (%) |
|---|---|
| Total number of cohorts | 26 (100%) |
| Publication year | |
| (2006-2012) | 10 (38.5) |
| (2013-2016) | 16 (61.5) |
| Median age | |
| < 75 years | 16 (61.5) |
| ≥ 75 years | 10 (38.5) |
| Percentage of males | |
| < 50 | 4 (15.4) |
| ≥50 | 21 (74.) |
| Not reported | 1(3.8) |
| Percentage of patients with ECOG scores of ≤ 1 | |
| < 75 | 7 (26.9) |
| ≥75 | 10 (38.5) |
| Not reported | 9 (34.6) |
| Median bone marrow blast percentage | |
| < 50 | 9 (34.6) |
| ≥50 | 7 (26.9) |
| Not reported | 10 (38.5) |
| Treatment cohorts | |
| Azacitidine | 13 (50) |
| Decitabine | 7 (26.9) |
| Cytarabine | 3 (11.5) |
| Others (Intensive chemotherapy, Supportive Care) | 3(11.5) |